Category Research

Newron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…

Read MoreNewron Starts Phase III ENIGMA-TRS Trial of Evenamide for Treatment-Resistant Schizophrenia

PureTech Launches Celea Therapeutics to Revolutionize Respiratory Disease Treatment

PureTech Health Launches Celea Therapeutics to Transform the Treatment Landscape for Respiratory Diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company committed to developing groundbreaking therapies for patients with devastating conditions, has announced…

Read MorePureTech Launches Celea Therapeutics to Revolutionize Respiratory Disease Treatment

NorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman

NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive Chairman, Marking a Key Step in Leadership Succession for Continued Growth in the Radiopharmaceutical Sector NorthStar Medical Technologies, LLC, a recognized global innovator in the development, production, and commercialization of advanced radiopharmaceuticals…

Read MoreNorthStar Medical Technologies Names Jon Coulter as Non-Executive Chairman

Tahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Tahoe Therapeutics Secures $30 Million to Build the World’s Largest Dataset for Training AI-Powered Human Cell Models, Aiming to Transform Precision Medicine Tahoe Therapeutics, a biotechnology company at the intersection of artificial intelligence and cellular biology, has announced the successful…

Read MoreTahoe Therapeutics Secures $30M to Develop World’s Largest Human Cell AI Training Dataset

Charles River Associates Broadens Reach with Expansion of Life Sciences Practice

Charles River Associates Expands Life Sciences Practice with Appointment of Two Seasoned Industry Leaders Charles River Associates (NASDAQ: CRAI), a globally recognized leader in economic, financial, and management consulting, has announced a strategic expansion of its Life Sciences Practice with…

Read MoreCharles River Associates Broadens Reach with Expansion of Life Sciences Practice

Roche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD

Roche’s Susvimo Shows Durable Vision Preservation Over Five Years with Twice-Yearly Treatment in Neovascular AMD Roche has released compelling new long-term data highlighting the extended efficacy, safety, and durability of its innovative eye implant therapy, Susvimo® (ranibizumab injection), for individuals…

Read MoreRoche’s Susvimo Preserves Vision for 5 Years with Twice-Yearly Dosing in nAMD

Altasciences and VoxCell Partner to Boost Preclinical Drug Development

Altasciences and VoxCell BioInnovation Forge Strategic Partnership to Revolutionize Preclinical Drug Development with 3D Bioprinted Human Tissue Models In a move poised to reshape the landscape of early-stage drug development, Altasciences, a fully integrated drug development solution provider, and VoxCell…

Read MoreAltasciences and VoxCell Partner to Boost Preclinical Drug Development

Simulations Plus and Polish Academy Validate AI-Powered ADMET Predictor® Models

Simulations Plus and Polish Academy Scientists Validate AI-Powered Drug Design Models in Breakthrough Discovery Targeting Inflammation and Immune Regulation Simulations Plus, Inc. (Nasdaq: SLP), a prominent developer of modeling and simulation software for the biopharmaceutical industry, in collaboration with the…

Read MoreSimulations Plus and Polish Academy Validate AI-Powered ADMET Predictor® Models

Centauri Therapeutics Secures $5.1M from CARB-X for ABX-01 Human Trials

Centauri Therapeutics Secures Additional $5.1M from CARB-X to Propel Lead Antibacterial Candidate ABX-01 Into First-in-Human Trials Centauri Therapeutics Limited, an innovative immunotherapy company leveraging a novel platform for combating infectious diseases, announced today it has been awarded an additional $5.1…

Read MoreCentauri Therapeutics Secures $5.1M from CARB-X for ABX-01 Human Trials